BR112018068055A2 - métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas - Google Patents
métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticasInfo
- Publication number
- BR112018068055A2 BR112018068055A2 BR112018068055A BR112018068055A BR112018068055A2 BR 112018068055 A2 BR112018068055 A2 BR 112018068055A2 BR 112018068055 A BR112018068055 A BR 112018068055A BR 112018068055 A BR112018068055 A BR 112018068055A BR 112018068055 A2 BR112018068055 A2 BR 112018068055A2
- Authority
- BR
- Brazil
- Prior art keywords
- dna
- methods
- fusion proteins
- diphtheria toxin
- therapeutic uses
- Prior art date
Links
- 102000016607 Diphtheria Toxin Human genes 0.000 title 1
- 108010053187 Diphtheria Toxin Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 4
- 239000013604 expression vector Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000014493 regulation of gene expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306281P | 2016-03-10 | 2016-03-10 | |
| PCT/US2017/021715 WO2017156356A1 (en) | 2016-03-10 | 2017-03-10 | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068055A2 true BR112018068055A2 (pt) | 2019-01-08 |
Family
ID=59789900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068055A BR112018068055A2 (pt) | 2016-03-10 | 2017-03-10 | métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10988512B2 (https=) |
| EP (1) | EP3426785A4 (https=) |
| JP (2) | JP2019512233A (https=) |
| KR (1) | KR102430891B1 (https=) |
| CN (2) | CN118599011A (https=) |
| AU (1) | AU2017230792B2 (https=) |
| BR (1) | BR112018068055A2 (https=) |
| CA (1) | CA3017143A1 (https=) |
| IL (2) | IL261660A (https=) |
| MX (1) | MX2018010850A (https=) |
| WO (2) | WO2017156356A1 (https=) |
| ZA (1) | ZA201806450B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3762401A4 (en) * | 2018-03-06 | 2021-12-08 | The Johns Hopkins University | CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| MX2022000052A (es) * | 2019-07-01 | 2022-04-06 | Eisai R&D Man Co Ltd | Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. |
| EP3845556A1 (fr) * | 2019-12-31 | 2021-07-07 | Peptinov SAS | Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| KR20230102682A (ko) * | 2021-12-30 | 2023-07-07 | (주)셀트리온 | 목적 단백질의 발현 방법 |
| CN114903896B (zh) * | 2022-05-30 | 2023-07-25 | 广西大学 | 贝达喹啉在制备治疗弓形虫病药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2549855B1 (fr) * | 1983-07-29 | 1987-03-27 | Grp Genie Genetique | Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| CA1340494C (en) * | 1988-05-19 | 1999-04-13 | The Beth Israel Hospital Association And Brigham And Women's Hospital | Induction of tolerance to a foreign antigen |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| WO1991013090A1 (en) | 1990-03-02 | 1991-09-05 | Diane Williams | Improved chimeric toxins |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| NO175188C (no) * | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5654273A (en) | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2004007663A2 (en) | 2002-05-22 | 2004-01-22 | Advanced Microbial Solutions Corporation | Gene expression using metal ion dependent repressor/operator tandems |
| EP1687016A4 (en) * | 2003-11-25 | 2009-07-29 | Anjin Corp | GENETIC VARIANT OF DIPHTHERIC TOXIN |
| AU2006260240B2 (en) * | 2005-06-21 | 2012-03-15 | The Research Foundation For Microbial Diseases Of Osaka University | Therapeutic agent for cancer |
| AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2600843B9 (en) * | 2010-07-19 | 2020-03-11 | Pressure BioSciences, Inc. | Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
| WO2012039954A2 (en) * | 2010-09-08 | 2012-03-29 | The Scripps Research Institute | Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
| WO2012110596A1 (en) * | 2011-02-16 | 2012-08-23 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fusion protein for the treatment of immunologic or allergic reactions |
| KR101895768B1 (ko) * | 2011-06-01 | 2018-09-07 | 시아먼 유니버시티 | 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질 |
| US8906681B2 (en) * | 2011-08-02 | 2014-12-09 | The Scripps Research Institute | Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
-
2017
- 2017-03-10 JP JP2018547409A patent/JP2019512233A/ja active Pending
- 2017-03-10 EP EP17764163.6A patent/EP3426785A4/en active Pending
- 2017-03-10 BR BR112018068055A patent/BR112018068055A2/pt not_active Application Discontinuation
- 2017-03-10 KR KR1020187029101A patent/KR102430891B1/ko active Active
- 2017-03-10 MX MX2018010850A patent/MX2018010850A/es unknown
- 2017-03-10 AU AU2017230792A patent/AU2017230792B2/en active Active
- 2017-03-10 US US16/083,848 patent/US10988512B2/en active Active
- 2017-03-10 CN CN202410629953.8A patent/CN118599011A/zh active Pending
- 2017-03-10 CA CA3017143A patent/CA3017143A1/en active Pending
- 2017-03-10 WO PCT/US2017/021715 patent/WO2017156356A1/en not_active Ceased
- 2017-03-10 CN CN201780025215.0A patent/CN109790545A/zh active Pending
- 2017-09-11 WO PCT/US2017/051020 patent/WO2018164712A1/en not_active Ceased
-
2018
- 2018-09-06 IL IL261660A patent/IL261660A/en unknown
- 2018-09-27 ZA ZA2018/06450A patent/ZA201806450B/en unknown
-
2022
- 2022-03-22 IL IL291586A patent/IL291586A/en unknown
- 2022-11-04 JP JP2022177061A patent/JP7532475B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109790545A (zh) | 2019-05-21 |
| WO2017156356A1 (en) | 2017-09-14 |
| CA3017143A1 (en) | 2017-09-14 |
| US20190071472A1 (en) | 2019-03-07 |
| CN118599011A (zh) | 2024-09-06 |
| KR102430891B1 (ko) | 2022-08-09 |
| ZA201806450B (en) | 2020-12-23 |
| IL291586A (en) | 2022-05-01 |
| EP3426785A1 (en) | 2019-01-16 |
| MX2018010850A (es) | 2019-05-15 |
| AU2017230792A1 (en) | 2018-10-18 |
| JP2019512233A (ja) | 2019-05-16 |
| WO2018164712A1 (en) | 2018-09-13 |
| EP3426785A4 (en) | 2019-12-25 |
| AU2017230792A8 (en) | 2018-11-29 |
| IL261660A (en) | 2018-10-31 |
| JP2023011857A (ja) | 2023-01-24 |
| AU2017230792B2 (en) | 2023-08-10 |
| KR20190016934A (ko) | 2019-02-19 |
| US10988512B2 (en) | 2021-04-27 |
| JP7532475B2 (ja) | 2024-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068055A2 (pt) | métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
| BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
| BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
| AU2018298422A1 (en) | Novel nucleic acid molecules | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| BR112019010972A2 (pt) | receptores de células t e imunoterapia usando os mesmos | |
| BR112019001532A2 (pt) | proteínas de capsídeo de vírus adenoassociado inovadoras | |
| EA201992609A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
| MX2018009225A (es) | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| WO2015198243A3 (en) | Compositions and methods for long acting proteins | |
| MX2016015594A (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina. | |
| BR112017001463A2 (pt) | célula hospedeira melhorada para produzir proteínas | |
| BR112015013004A2 (pt) | molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| NZ752941A (en) | Frataxin expression constructs | |
| NZ724196A (en) | Uti fusion proteins | |
| EA201891141A1 (ru) | Новые антиангиогенные слитые полипептиды | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |